Loading
A phase 1 trial of Amsokigene autoleucel run by M.D. Anderson Cancer Center, active and no longer recruiting.
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma is a phase 1 interventional study registered as NCT05470283 by M.D. Anderson Cancer Center, with 21 participants planned, started 2022-09-07. Conditions recorded: Tumor, Metastatic Melanoma and Melanoma. Interventions recorded: OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna and Fludarabine Phosphate.
Shares Amsokigene autoleucel, Obsidian Therapeutics, Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/